About Us

For many years the Company has progressively exploited its proprietary epigenetic technology and this work has led to the development of a novel and ground-breaking class of therapeutics across a number of fields in oncology and has taken ValiRx’s lead compound VAL201 into Phase I/II clinical trials.

The Company has a pipeline of other therapeutic drugs, which are currently progressing towards clinical trials and its VAL401 molecule, a joint venture compound with ValiSeek Ltd, recently peer reviewed following the completion of it’s phase 2 clinical trial.

Our product focus lies in the targeted analysis and treatment of cancer, however our technologies can be applied to other fields as well, such as neurology and inflammatory diseases.